Objective: Our knowledge of the molecular mechanisms of sepsis has attained exponential
growth. Yet, the pillars of its care remain antibiotics, fluid resuscitation, and physiologic
support of failing organ systems. The inability to bring biologic breakthroughs to the bedside
is not for lack of effort. Over 60 clinical trials of novel therapies, each heavily supported by
the momentum of biologic data suggesting clinical utility, have been conducted and have
failed to identify benefit. This mass of “negative” clinical data abut an equally towering …